Finance

Lists
PHVS:NASDAQ
Pharvaris NV
$31.42
-1.54%
(-0.49) 1D
Sep 29, 10:11:28 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PHVS...
Open
$31.93
High
$32.34
Low
$31.42
Mkt. cap
2.21B
Avg. vol.
957.80K
Volume
26.96K
52-wk high
$43.25
52-wk low
$20.65
EPS
-$2.98
Beta
-2.32
Shares outstanding
69.86M
No. of employees
148
Open
$31.93
High
$32.34
Low
$31.42
Mkt. cap
2.21B
Avg. vol.
957.80K
Volume
26.96K
52-wk high
$43.25
52-wk low
$20.65
EPS
-$2.98
Beta
-2.32
Shares outstanding
69.86M
No. of employees
148
News stories
From web sources and news partners
About Pharvaris NV
CEO-
Employees148
Founded2015
Headquarters-
SectorPharmaceutical industry
Websitepharvaris.com
Analyst ratings
Based on 12 analysts giving stock ratings to PHVS in the past 3 months
Strong buy
Buy
11
Hold
1
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for PHVS in the last 3 months.
Highest
Current $31.42
$79.00 (+151.43%)
Average
$61.33 (+95.19%)
Lowest
$44.00 (+40.04%)
Analyst
Recommendation
Action
Price target
Projected
Date
Maxwell Skor
Morgan Stanley
Buy
Reiterated
$62.00
+97.3%
09/28/2026
Patrick Trucchio
H.C. Wainwright
Buy
Maintained
$60.00
+91%
09/21/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$44.00
+40%
09/09/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Reiterated
$65.00
+106.9%
09/09/2026
Laura Chico
Wedbush
Buy
Maintained
$50.00
+59.1%
09/09/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$65.00
+106.9%
09/10/2026
Nevin Varghese
RBC Capital
Buy
Maintained
$62.00
+97.3%
09/09/2026
Debanjana Chatterjee
JonesTrading
Buy
Reiterated
$65.00
+106.9%
09/09/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
$65.00
+106.9%
09/09/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$79.00
+151.4%
09/09/2026
Tazeen Ahmad
Bank of America Securities
Hold
Reiterated
$44.00
+40%
09/08/2026
Justin Kim
Oppenheimer
Buy
Maintained
$75.00
+138.7%
09/08/2026
Jeff Jones
Oppenheimer
Buy
Maintained
$75.00
+138.7%
09/08/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$50.00
+59.1%
08/13/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$40.00
+27.3%
08/12/2026
Andy Chen
Wolfe Research
Buy
Initiated
$42.00
+33.7%
04/08/2026
Unknown Analyst
RBC Capital
Buy
Initiated
$52.00
+65.5%
03/09/2026
Last report
Aug 12, 2026
Fiscal period
Q2 2026
EPS / Est. (EUR)
-€0.70 / -€0.65
-7.24%miss
Revenue / Est. (EUR)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
29.81M
34.14M
30.16M
35.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.85M
13.46M
14.11M
15.79M
Operating expense
39.66M
47.60M
44.27M
50.79M
Total operating expenses
39.66M
47.60M
44.27M
50.79M
Operating income
-39.66M
-47.60M
-44.27M
-50.79M
Other non operating income
-
-
-86.40K
-72.60K
EBT including unusual items
-37.32M
-45.08M
-38.93M
-47.24M
EBT excluding unusual items
-37.32M
-45.08M
-38.93M
-47.24M
Income tax expense
-181.47K
1.66M
273.11K
602.20K
Effective tax rate
0.49%
-3.69%
-0.70%
-1.27%
Other operating expenses
-
-
-
-
Net income
-37.14M
-46.74M
-39.20M
-47.84M
Net profit margin
-
-
-
-
Earnings per share
-0.60
-0.71
-0.60
-0.70
Interest and investment income
2.15M
2.19M
1.67M
1.98M
Interest expense
-50.03K
-58.74K
-
-
Net interest expenses
2.10M
2.13M
1.67M
1.98M
Depreciation and amortization charges
-
-
-
-
EBITDA
-39.62M
-47.55M
-44.22M
-50.66M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps